Skip to main content
SpringerLink
Log in

The role of nuclear medicine in oncology

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Nuclear Medicine offers screening methods for oncology such as bone and bone marrow scintigraphy. During the last two decades, special procedures have gained widespread application. This paper is centered around the “tumor-specific” radiopharmaceuticals. In patients with thyroid cancer, I-131 still plays a significant role. Ga-67 still has its indications in lymphoma, while in other diseases Tl-201 cloride is now the agent of choice. Especially in thyroid cancer, Tl-201 has proved to be a reliable tumor imaging radiopharmaceutical. More recently, Tc-99m MIBI was introduced for tumor imaging. Tc-99m HMPAO may also be used for tumor scintigraphy, especially in brain lesions. In addition, I-123 IMP has successfully been used for imaging malignant melanoma. Another promising field of tumor diagnosis is receptor imaging. In neuroblastoma and malignant pheochromocytoma, I-131/123 mIBG is the radiopharmaceutical of choice and may be considered as a receptor imaging agent also. First clinical results with In-111 octreotide show potentials as somatostatine-receptor radiopharmaceutical in insulinoma, islet cell carcinoma, medullary and lung cancer, while I-123 estradiol needs some improvement until it may be recommended as diagnostic tool in breast cancer. Since 1978, radiolabeled poly- or monoclonal tumor antibodies and their fragments have gained widespread application. Especially the Tc-99m 225.28S melanoma antibody, I-131 or Tc-99m CEA and In-111/I-131 labeled OC-125 antibodies have proven to be of clinical significance in melanoma, colorectal and ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Briele B, Hotze AL, Grünwald F, et al: Erhöhte Sensitivität der Ganzkörperszintigraphie mit J-131 für den Nachweis jodspeichernder Metastasen durch spätere Aufnahmezeitpunkte.Nucl Med 29: 264–268, 1990

    CAS  Google Scholar 

  2. Pacini F, Lippi F, Formica N, et al: Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with undetectable serum thyroglobulin levels.J Nucl Med 28: 1888–1891, 1987

    CAS  PubMed  Google Scholar 

  3. Nemec J, Röhling S, Zamrazil V, et al: Comparison of the distribution of diagnostic and thyroablative 131-1 in the evaluation of differentiated thyroid cancers.J Nucl Med 20: 92–97, 1979

    CAS  PubMed  Google Scholar 

  4. Briele B, Hotze AL, Kropp J, et al: Vergleich von Tl-201 und Tc-99m-Mibi in der Nachsorge des differenzierten Schilddrüsenkarzinoms.Nucl Med 30: 115–124, 1991

    CAS  Google Scholar 

  5. Müller S, Paas M, Konietzko N, et al: Szintigraphie mit Tl-201 und Tc-99m-MIBI beim Schilddrüsen- und Bronchialkarzinom.Zbl Radiol 141: 206, 1990

    Google Scholar 

  6. Hoefnagel CA, Delprat HR, Marcuse HR, et al: Role of thallium-201 total body scintigraphy in the follow-up of thyroid carcinoma.J Nucl Med 27: 1854–1857, 1986

    CAS  PubMed  Google Scholar 

  7. Hassan IM, Sahweil A, Constantinides C, et al: Uptake and kinetics of Tc-99m-hexakis 2-methoxy isobutyl isonitrile in benign and malign lesions in the lungs.Clin Nucl Med 14: 333–340, 1989

    Article  CAS  PubMed  Google Scholar 

  8. Kostakoglu L, Yeh SDJ, Portlock C, et al: Validitation of Ga-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin’s disease in the mediastinum.J Nucl Med 33: 345–350, 1992

    CAS  PubMed  Google Scholar 

  9. Israel O, Front D, Lam M, et al: Ga-67 imaging in monitoring lymphoma response to treatment.Cancer 61: 2439–2443, 1988

    Article  CAS  PubMed  Google Scholar 

  10. Kirkwood JM, Myers JE, Vlock DR, et al: Tomographie Gallium-67 citrate scanning: Useful new surveillance for metastatic melanoma.Ann Intern Med 97: 694–699, 1982

    CAS  PubMed  Google Scholar 

  11. Botsch H:Galliumszintigraphie. Springer, Berlin Heidelberg, New York, Tokyo, 1985

    Google Scholar 

  12. Kubo K, Itoh K, Nakada K, et al: The visualization of squamous cell carcinoma of the skin with I-123 iodoamphetamine.Clin Nucl Med 14: 138, 1989

    Article  CAS  PubMed  Google Scholar 

  13. Cohen MB, Saxton RE, Lake RR, et al: Detection of malignant melanoma with iodine-123 iodoamphetamine.J Nucl Med 29: 1200–1206, 1988

    CAS  PubMed  Google Scholar 

  14. Babich JW, Kieling F, Flower NA, et al: Initial experience with Tc-99m HM-PAO in the study of brain tumors.Eur J Nucl Med 14: 39–44, 1988

    Article  CAS  PubMed  Google Scholar 

  15. Suess E, Malessa S, Ungersbröck K, et al:Tc-99m- HMPAO-Aufnahme und Glutathiongehalt zerebraler Tumoren. In: Höfer R, Bergmann H, (Eds): Radioaktive Isotope in Klinik und Forschung; Stuttgart, New York, 1988

    Google Scholar 

  16. Hammersley PAG, McCready VR, Babich JW, et al: Tc-99m-HMPAO as a tumor blood flow agent.Eur J Nucl Med 13: 90–94, 1987

    Article  CAS  PubMed  Google Scholar 

  17. McCready VR, Babich J, Flower MA, et al: The use of Tc-99m-HMPAO for tumor detection and the study of tumor blood flow,Nucl Med 27: 116–117, 1988

    Google Scholar 

  18. Biersack HJ, Grünwald F, Kropp J: Single-photon-emission-computed-tomography imaging of brain tumors.Sent Nucl Med 21: 2–10, 1991

    Article  CAS  Google Scholar 

  19. Biersack HJ, Coenen HH, Stöcklin G, et al: Imaging of brain tumors with L-3-(123I)iodo-alpha-methyl- tyrosine and SPECT.J Nucl Med 30: 110–112, 1989

    CAS  PubMed  Google Scholar 

  20. Langen KJ, Coenen HH, Rosen N, et al: SPECT Studies of brain tumors L-3-(123I)iodo-alpha-methyl-tyrosine: Comparison with PET, 124 IMT and first clinical results.J Nucl Med 31: 281–286, 1990

    CAS  PubMed  Google Scholar 

  21. Yokoyama A, Hata N, Horiuchi K, et al: The design of a pentavalent Tc-99m-dimercaptosuccinate complex as a tumor imaging agent.Int J Nucl Med Biol 12: 273–279, 1985

    Article  CAS  PubMed  Google Scholar 

  22. Watkinson JC, Lazarus CR, Mistry R, et al: Technetium-99m-(V)dimercaptosuccinic acid uptake in patients with squamous carcinoma of the head and neck—experience in imaging.J Nucl Med 30: 174–180, 1989

    CAS  PubMed  Google Scholar 

  23. Zielinski JE, Yabuki H, Pahuja SL, et al: 16-(J-123) iodo-11u methoxy-17u-estradiol: a radiochemical probe for estrogen-sensitive tissues.Endocrinology 119: 130–139, 1986

    Article  CAS  PubMed  Google Scholar 

  24. Scheidhauer K, Müller S, Smolarz K, et al: Tumor-Szintigraphie mit J-123-markiertem Östradiol beim Mammakarzinom-Rezeptorszintigraphie.Nucl Med 30: 84–99, 1991

    CAS  Google Scholar 

  25. Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma.N Engl J Med 305: 12–17, 1981

    Article  CAS  PubMed  Google Scholar 

  26. Fischer M, Vetter W, Winterberg B, et al: J-131-metaiodobenzylguanidine—a new agent for scintigraphic imaging and treatment of pheochromocytoma.Nucl Med 23: 77–79, 1984

    CAS  Google Scholar 

  27. Lamberts SWJ, Bakker WH, Reubi JC, et al: Somatostatin-receptor imaging in the localization of endocrine tumours.N Engl J Med 323: 1246–1249, 1990

    CAS  PubMed  Google Scholar 

  28. Bakker WH, Krenning EP, Breeman WAP, et al:In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism and binding to somatostatin receptor positive tumours in man.J Nucl Med 32: 1184–1188, 1991

    CAS  PubMed  Google Scholar 

  29. Buraggi SL: Radioimmunodetection of malignant melanoma with the 225.28S monoclonal antibody to HMW-MAA.Nucl Med 25: 220–224, 1986

    CAS  Google Scholar 

  30. Saxton RE, Burke MW, Torbet B, et al: Detection of malignant melanoma with monoclonal antibodies.Dis Markers 6: 97–108, 1988

    CAS  PubMed  Google Scholar 

  31. Scheidhauer K, Markl A, Leinsinger G, et al: Immunoscintigraphy in intraocular malignant melanoma.Nucl Med Comm 9: 669–678, 1988

    Article  CAS  Google Scholar 

  32. Bockisch A, Brökelmann J, Briele B, et al: Radio-immunodetection (RID) with OC-125 antibody F(ab’)2 fragments in the follow-up of ovarian carcinoma.Med Nucl 2: 281–288, 1990

    Google Scholar 

  33. Gitsch E, Pateisky N: Radioimmunoscintigraphy in ovarian cancer: Theoretical basis and clinical results.Arch Gyn Obstet 241: 365–370, 1987

    Article  Google Scholar 

  34. Baum RP, Lorenz M, Hottenrott C, et al: Radio-immunoscintigraphy using monoclonal antibodies to CE A, CA 19-9 and CA 125.Int J Biol Markers 3: 177–184, 1988

    CAS  PubMed  Google Scholar 

  35. Chatal JF, Saccavini JC, Fumoleau P, et al: Immuno-scintigraphy of colon carcinoma.J Nucl Med 25: 307–314, 1984

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, Universität Bonn, Sigmund-Freud-Straße 25, 5300, Bonn 1, Germany

    Hans J. Biersack, Bernd Briele, Andreas L. Hotze, Peter Oehr & Liu Qian

  2. Department of Radiotherapy and Nuclear Medicine, Assiut University Hospital, Egypt

    Mohamed A. Mekkawy

  3. Department of Veterans Affairs Medical Center, Nuclear Medicine Service, Lexington, KY

    Wei-Jen Shih

Authors
  1. Hans J. Biersack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd Briele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas L. Hotze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Oehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liu Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamed A. Mekkawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei-Jen Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biersack, H.J., Briele, B., Hotze, A.L. et al. The role of nuclear medicine in oncology. Ann Nucl Med 6, 131–136 (1992). https://doi.org/10.1007/BF03178304

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03178304

Key words

Search

Navigation